Novavax submits application to Health Canada for updated protein-based 2024-2025 formula COVID-19 vaccine

2 July 2024 - Novavax's filing is aligned with NACI, US. FDA, EMA and WHO recommendations on vaccine composition. ...

Read more →

Pfizer and BioNTech receive positive CHMP opinion for omicron JN.1 adapted COVID-19 Vaccine in the European Union

27 June 2024 - The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for ...

Read more →

Novavax submits application to EMA for updated protein-based 2024-2025 formula COVID-19 vaccine

24 June 2024 - Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 ...

Read more →

Novavax submits application to US FDA for updated protein based 2024-2025 formula COVID-19 vaccine

14 June 2024 - Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3. ...

Read more →

Moderna files FDA application for the JN.1 targeting COVID-19 vaccine

7 June 2024 - Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as ...

Read more →

Updated COVID-19 vaccines for use in the United States beginning in fall 2024

7 June 2024 - The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met on 5 June 2024 to ...

Read more →

Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease (final guidance)

8 May 2024 - NICE has published final evidence-based recommendations on the use of remdesivir (Veklury) and tixagevimab and cilgavimab ...

Read more →

PHARMAC and Health NZ weigh up future of COVID-19 vaccines and treatments

3 May 2024 - PHARMAC and Health NZ are weighing up the future direction of COVID-19 vaccinations and treatments in ...

Read more →

COVID-19 vaccine strain updates: global regulators agree on timing and data requirements

17 April 2024 - International regulators have published a report today presenting the outcomes of a workshop on COVID-19 vaccine ...

Read more →

NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld) for treatment of COVID-19

9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE. ...

Read more →

COVID-19 2024 vaccine advice

29 February 2024 - The Australian Government has accepted the latest advice from the Australian Technical Advisory Group on Immunisation ...

Read more →

COVID-19 vaccine available in March

22 February 2024 - Joint media release with Health New Zealand. ...

Read more →

MHRA approvals for Comirnaty (Pfizer/BioNTech) and Nuvaxovid (Novavax) COVID-19 vaccines

10 February 2024 - Approval of a change to the licence of Comirnaty COVID-19 vaccine will enable thawing and re-labelling of ...

Read more →

Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease

18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...

Read more →

NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19

18 January 2024 - Draft guidance for public consultation has been published by NICE. ...

Read more →